Clinical Trials

51 enrolled

Lymphoma, T-Cell, Peripheral

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT06519526 2026-03-24

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

25 enrolled

Lymphoma, T-Cell, Peripheral

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT06630091 2026-02-17

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

30 enrolled

Phase 2 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

50 enrolled

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07180771 2026-01-28

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

44 enrolled

Lymphoma, T-Cell, Peripheral

NCT06511895 2025-12-24

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

57 enrolled

Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

53 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

31 enrolled

Phase 2 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

155 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 enrolled

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06160843 2025-09-05

POLAR

24 enrolled

Lymphoma, T-Cell, Peripheral

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

71 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT06511869 2025-07-04

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

48 enrolled

Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

35 enrolled

Lymphoma, T-Cell, Peripheral

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

115 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT06941688 2025-04-24

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

Phase 2 Terminated

17 enrolled

Lymphoma, T-Cell, Peripheral

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

32 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

33 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03372057 2025-03-07

PRIMO

156 enrolled 21 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

DermatologicLymphoidOther hematologic neoplasm

6 enrolled 11 charts

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

NCT06151106 2025-02-19

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

33 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT05958719 2024-12-30

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

37 enrolled

Lymphoma, T-Cell, Peripheral

NCT06702605 2024-11-25

To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT04101331 2024-11-05

REDIRECT

108 enrolled 24 charts

Lymphoma, T-Cell, Peripheral

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

77 enrolled 20 charts

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

55 enrolled 18 charts

Phase 2 Active not recruiting

Lymphoma, T-Cell, Peripheral

NCT06550336 2024-08-29

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

35 enrolled

Lymphoma, T-Cell, Peripheral

NCT05140382 2024-08-28

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

52 enrolled 24 charts

Recurrence, Lymphoma, T-Cell, Peripheral

NCT06468267 2024-08-01

RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT02464228 2024-06-26

PTCL

65 enrolled 16 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT01611142 2024-06-17

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

LymphoidOther hematologic neoplasm

38 enrolled

Neoplasms, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT06433362 2024-05-29

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

115 enrolled

Lymphoma, T-Cell, Peripheral

NCT01226472 2024-04-25

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

1 enrolled 5 charts

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02232516 2024-04-10

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2 Unknown

30 enrolled 17 charts

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02653976 2024-01-26

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

67 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT00571662 2023-10-24

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

76 enrolled 10 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03947255 2023-10-13

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Phase 2 Terminated

12 enrolled 17 charts